



ASX Announcement

December 7, 2021

CHIMERIC EXCLUSIVE OPTION TO LICENSE CORE-NK PLATFORM (supplementary announcement)

Further to the announcement of the exclusive option to license the CORE-NK platform released on 1 December 2021, at the request of the ASX, Chimeric Therapeutics (ASX:CHM, “Chimeric” or the “Company”), a clinical-stage cell therapy company and the ASX leader in cell therapy, provides additional information regarding exclusive option to license agreement with Case Western Reserve University (CWRU) for a **Clinically validated, Off the shelf, Robust, Enhanced Natural Killer (CORE-NK)** cell platform – a platform technology that provides the optimal foundation for the development of multiple next generation NK and CAR-NK products.

Under the terms of the option to license agreement, Chimeric has the exclusive right to license the CORE-NK platform for development and commercialization in cancer for a period of six months, commencing immediately. Chimeric intends to rapidly move to complete full licensing of the platform and expects to pay CWRU development milestones and industry standard royalty payments based on commercial net sales. Upfront fees associated with the option agreement will be funded entirely from the existing research budget. Chimeric may exercise the license option at any time within the six-month option period, provided it fulfils certain milestones in accordance with an agreed development plan.

Authorised on behalf of the Chimeric Therapeutics board of directors by Chairman Paul Hopper.

ABOUT CHIMERIC THERAPEUTICS

Chimeric Therapeutics, a clinical stage cell therapy company and the ASX leader in cell therapy, is focused on bringing the promise of cell therapy to life for more patients with cancer. We believe that cellular therapies have the promise to cure cancer not just delay disease progression.

To bring that promise to life for more patients, Chimeric’s world class team of cell therapy pioneers and experts is focused on the discovery, development, and commercialization of the most innovative and promising cell therapies.



CHM 1101 (CLTX CAR T) is a novel and promising CAR T therapy developed by scientists at the City of Hope Medical Centre in California for the treatment of patients with solid tumours. CHM 1101 is currently being studied in a phase 1 clinical trial in recurrent/ progressive glioblastoma. A 2nd CLTX CAR T phase 1 clinical trial is planned to begin in 2022 in additional solid tumours.

CHM 2101 (CDH17 CAR T) is a novel, 3rd generation CDH17 CAR T invented at the University of Pennsylvania. CHM 2101 (CDH17 CAR T) is currently in preclinical development with a planned phase 1 clinical trial in 2022 in Neuroendocrine Tumours, Colorectal, Pancreatic and Gastric Cancer.

Chimeric Therapeutics continues to be actively engaged in further developing its oncology pipeline with new and novel cell therapy assets that will bring the promise of cell therapy to life for more patients with cancer.

CONTACT

Investors

Jennifer Chow
Chief Executive Officer and Managing Director
Chimeric Therapeutics
T: + 1 9087238387
E: jchow@chimerictherapeutics.com
W: www.chimerictherapeutics.com

Paul Hopper
Executive Chairman
T: + 61 406 671 515
E: paulhopper@lifescienceportfolio.com

Media

Matthew Wright
NWR Communications
P: +61 451 896 420
E: matt@nwrcommunications.com.au